AstraZeneca Invests $285 Million in New Facility
AstraZeneca announces that it will invest $285 million in a new manufacturing facility in Sweden.
AstraZeneca announced on May 18, 2015 plans to build a $285 million-manufacturing facility for biological medicines, specifically filling and packaging of protein therapeutics, in Södertälje, Sweden. The investment is the first of a three-part program to expand AstraZeneca’s biologics manufacturing capabilities. AstraZeneca’s largest global tablets and capsules manufacturing facility and launch platform site is also located in Södertälje.
“This is a strategically important investment for AstraZeneca to support the accelerating development of biotech medicines, which now make up around half of our pipeline. We expect to bring a significantly increased number of new specialty care medicines to patients in the coming years, driven in large part by biologics. This new plant will give us greater capacity and flexibility to handle clinical trials, and will also play an important role in our future commercial production,” said Pascal Soriot, CEO of AstraZeneca, in a press release.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
